Use of a manganese-containing compound for reducing uric acid levels in a mammalian subject

JP2025524726A5Pending Publication Date: 2026-06-26SHANGHAI SHIQU PHARM TECH CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Applications
Current Assignee / Owner: SHANGHAI SHIQU PHARM TECH CO LTD
Filing Date: 2023-07-14
Publication Date: 2026-06-26

Application Information

Patent Timeline

14 Jul 2023

Application

26 Jun 2026

Publication

JP2025524726A5

IPC: A61K33/32; A61P19/06; A61K9/14; A61K9/20; A61K9/48; A61K9/16; A61P3/10; A61P3/06; A61P5/14; A61P5/18; A61P3/04; A61P29/00; A61P21/00; A61P19/02; A61P35/00; A61P7/00; A61P25/28; A61P17/06; A61P1/16; A61P9/10; A61P9/04; A61P7/06; A61P3/00; A61P39/02; A61P15/00; A61P13/12; A61P9/12; A61P9/00; A61P27/02; A61P11/00

CPC: A61K33/32; A61K45/06; A61P19/06; A61P13/12; A61P9/00; A61P35/02; A61P1/16; A61P39/02

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗

Get free access to AI patent search and analysis

Check patentability, review prior art and ask IP Agent with full patent context.

AI Technical Summary

Technical Problem

Current treatments for hyperuricemia and gout are inadequate in reducing uric acid levels and are often accompanied by harmful side effects, while existing drugs that act locally in the digestive tract do not effectively lower systemic uric acid levels.

Method used

The use of insoluble manganese-containing compounds, such as manganese oxide, to adsorb and remove uric acid in the gastrointestinal tract, which are not affected by digestive fluids and can be administered at high doses without causing unacceptable side effects.

Benefits of technology

Insoluble manganese-containing compounds effectively reduce uric acid levels in the blood and gastrointestinal tract, providing a safe and complementary approach to existing treatments by maintaining uric acid levels within the normal range and preventing associated disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

Figure 00000000_0000_ABST

Patent Text Reader

Abstract

Use of a manganese-containing compound for reducing uric acid levels in a mammalian subject. In particular, the present invention relates to the use of an insoluble manganese-containing compound in the preparation of a medicament for preventing and / or treating an increase in the level of uric acid in the blood and / or gastrointestinal tract of a mammalian subject, or a disease or condition associated with an increase in the level of uric acid in the blood and / or gastrointestinal tract, a pharmaceutical composition, a kit for such use, and a method for preventing and / or treating related diseases or conditions.

Need to check novelty before this filing date? Find Prior Art